<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25896788</article-id><article-id pub-id-type="pmc">4404563</article-id><article-id pub-id-type="publisher-id">56</article-id><article-id pub-id-type="doi">10.1186/s12882-015-0056-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Protein-bound solute removal during extended multipass <italic>versus</italic> standard hemodialysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Eloot</surname><given-names>Sunny</given-names></name><address><email>sunny.eloot@ugent.be</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Van Biesen</surname><given-names>Wim</given-names></name><address><email>wim.vanbiesen@ugent.be</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Axelsen</surname><given-names>Mette</given-names></name><address><email>metaxels@rm.dk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Glorieux</surname><given-names>Griet</given-names></name><address><email>griet.glorieux@ugent.be</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Robert Smith</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Heaf</surname><given-names>James Goya</given-names></name><address><email>d110582@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Department of Nephrology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium </aff><aff id="Aff2"><label/>Institute of Public Health, Aarhus University, Nordre Ringgade 1, 8000 Aarhus C, Denmark </aff><aff id="Aff3"><label/>Flexdialysis Aps, Copenhagen, Denmark </aff><aff id="Aff4"><label/>Department of Nephrology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>57</elocation-id><history><date date-type="received"><day>12</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Eloot et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Multipass hemodialysis (MPHD) is a recently described dialysis modality, involving the use of small volumes of dialysate which are repetitively recycled. Dialysis regimes of 8&#x000a0;hours for six days a week using this device result in an increased removal of small water soluble solutes and middle molecules compared to standard hemodialysis (SHD). Since protein-bound solutes (PBS) exert important pathophysiological effects, we investigated whether MPHD results in improved removal of PBS as well.</p></sec><sec><title>Methods</title><p>A cross-over study (Clinical Trial NCT01267760) was performed in nine stable HD patients. At midweek a single dialysis session was performed with either 4&#x000a0;hours SHD using a dialysate flow of 500&#x000a0;mL/min or 8&#x000a0;hours MPHD with a dialysate volume of 50% of estimated body water volume. Blood and dialysate samples were taken every hour to determine concentrations of p-cresylglucuronide (PCG), hippuric acid (HA), indole acetic acid (IAA), indoxyl sulfate (IS), and p-cresylsulfate (PCS). Dialyser extraction ratio, reduction ratio, and solute removal were calculated for these solutes.</p></sec><sec><title>Results</title><p>Already at 60&#x000a0;min after dialysis start, the extraction ratio in the hemodialyser was a factor 1.4-4 lower with MPHD versus SHD, resulting in significantly smaller reduction ratios and lower solute removal within a single session. Even when extrapolating our findings to 3 times 4&#x000a0;h SHD and 6 times 8&#x000a0;h MPHD per week, the latter modality was at best similar in terms of total solute removal for most protein-bound solutes, and worse for the highly protein-bound solutes IS and PCS. When efficiency was calculated as solute removal/litre of dialysate used, MPHD was found superior to SHD.</p></sec><sec><title>Conclusion</title><p>When high water consumption is a concern, a treatment regimen of 6 times/week 8&#x000a0;h MPHD might be an alternative for 3 times/week 4&#x000a0;h SHD, but at the expense of a lower total solute removal of highly protein-bound solutes.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Solute removal</kwd><kwd>Recirculation</kwd><kwd>Water consumption</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>To overcome the non-physiological characteristics of standard 3 times/week 4&#x000a0;hour in-centre hemodialysis, alternative dialysis regimens are being developed, aiming to reduce labour costs and patient burden, and increase patient comfort and solute removal [<xref ref-type="bibr" rid="CR1">1</xref>-<xref ref-type="bibr" rid="CR14">14</xref>]. In addition, production of dialysate is being recognized as having an important financial and ecological cost, which is likely to even increase in the future [<xref ref-type="bibr" rid="CR15">15</xref>]. There is an increasing interest in these alternative renal replacement therapies, whereby either duration of a single session (extended dialysis) [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR14">14</xref>], the frequency per week (frequent dialysis) [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR13">13</xref>] or a combination thereof [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR12">12</xref>] are different from standard 3 times/week dialysis. For most of these settings, regular dialysis monitors are used, with online production of dialysate. Some alternative approaches have been proposed, whereby either dialysate is prepared as a batch [<xref ref-type="bibr" rid="CR16">16</xref>-<xref ref-type="bibr" rid="CR18">18</xref>], or is available in industrially prepared bags [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Recently, multipass hemodialysis (MPHD) was described as a feasible, economic and ecologic alternative to deliver home hemodialysis [<xref ref-type="bibr" rid="CR20">20</xref>]. A regime of daily nocturnal dialysis eight hours six times a week, using a dialysate bath of one half of the calculated total body water, i.e. 20-25&#x000a0;L, which is continually recycled at a dialysate flow of 500&#x000a0;mL/min, while blood flow is conventional (&#x0003e;200&#x000a0;mL/min) was proposed as treatment paradigm. Obvious advantages are the ease of use, and the low water consumption, making the technique ideal for home hemodialysis. Using this technique, a significantly higher weekly removal was obtained for small water soluble solutes and for middle molecules like &#x003b2;<sub>2</sub>-microglobulin, as compared to 3 times 4&#x000a0;h standard hemodialysis (SHD) [<xref ref-type="bibr" rid="CR20">20</xref>]. Since higher middle molecule removal has been linked to reduced mortality [<xref ref-type="bibr" rid="CR21">21</xref>], and due to the limited dialysate consumption, MPHD seems to be a very promising technique for performing (portable) home hemodialysis.</p><p>Protein-bound solutes are known as difficult to remove by conventional hemodialysis as the ligand proteins often have a molecular weight above or at the borderline of the cut-off of currently used high flux dialysis membranes. This lack of adequate removal may have important clinical consequences, since several protein-bound solutes have been linked to progression of renal failure, inflammation, vascular disease, and mortality [<xref ref-type="bibr" rid="CR22">22</xref>-<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>The present study was set up to investigate removal of protein-bound solutes by 8&#x000a0;h MPHD as compared to 4&#x000a0;h SHD.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients</title><p>The patients and methods have been described in a previous publication [<xref ref-type="bibr" rid="CR20">20</xref>]. Ten stable HD patients, all receiving standard in-centre HD three times per week were included in the original study, but, due to sample corruption, only nine are included in the present study. Exclusion criteria were: age less than 18&#x000a0;years, psychiatric disease, ultrafiltration requirement more than 4&#x000a0;L per session, possibility of pregnancy and severe comorbidity. Prior to the study, catheter/fistula recirculation was excluded using the indicator dilution technique and the Krivitski method (HD 01 plus, Transonic Systems, Ithaca, New York State). All patients gave written informed consent according to the Helsinki II declaration. The protocol was approved by the local ethics committee &#x02018;Videnskabsetiske Komit&#x000e9; for Hovedstads Region&#x02019; (identification number H-2-2009-082) and registered on ClinicalTrials.gov (identification number NCT01267760).</p></sec><sec id="Sec4"><title>Study design</title><p>Each patient was studied twice with a one week interval. The patients used either the Polyflux 170H (3 patients) or Polyflux 210H with a surface area of 1.7 and 2.1&#x000a0;m<sup>2</sup>, respectively (Gambro, Lund, Sweden) for both sessions. The reference treatment was standard hemodialysis (SHD) lasting 4&#x000a0;hours, with a dialysate flow of 500&#x000a0;mL/min. The dialysate was continuously collected in a chamber placed on electronic weighing scales. A blender was placed in the chamber to assure adequate mixing before sampling.</p><p>The alternative treatment was multipass hemodialysis (MPHD) using a dialysate chamber with a volume corresponding to 50% of the patient&#x02019;s total body water (TBW), which was estimated as either 55% (female) or 60% (male) of dry weight. One patient, with a body weight of 111&#x000a0;kg and an estimated TBW of 66&#x000a0;L was only treated with 30.4&#x000a0;L due to the limitations of the dialysate chamber. The dialysate was prepared by the AK-200 dialysis machine (Gambro, Lund, Sweden), and was identical for both treatments. With MPHD, dialysate was recirculated via the chamber which was placed on electronic scales, and in which an oscillation mechanism was installed to assure optimal mixing. Two pumps controlled dialysate inflow (500&#x000a0;mL/min - UF/2) and outflow (500&#x000a0;mL/min&#x02009;+&#x02009;UF/2), and thus ultrafiltration (UF). Dialysate temperature was set at 36-37&#x000b0;C at the dialyser inlet, and was continuously registered.</p><p>Fractionated heparin was used as anticoagulation, at the patient&#x02019;s usual dose (at the start of SHD and MPHD). After 4&#x000a0;hours MPHD a new similar bolus was administered.</p></sec><sec id="Sec5"><title>Sampling and analysis</title><p>Blood samples were collected from the inlet blood line at the start and at hourly intervals. In addition, one blood sample was taken from the blood outlet line at 60&#x000a0;min to obtain the dialyser extraction ratio. Blood samples were immediately centrifuged at 3000&#x000a0;rpm, after which the plasma was stored at &#x02212;80&#x000b0;C until batch analysis. From the dialysate chamber, dialysate was sampled hourly and stored at &#x02212;80&#x000b0;C.</p><p>Different protein-bound solutes were determined by high performance liquid chromatography (HPLC): p-cresylglucuronide (PCG) (molecular weight MW:284&#x000a0;Da, protein binding PB&#x02009;~&#x02009;10%), hippuric acid (HA - 179&#x000a0;Da - PB&#x02009;~&#x02009;50%), indole acetic acid (IAA - 175&#x000a0;Da - PB&#x02009;~&#x02009;65%), indoxyl sulfate (IS - 213&#x000a0;Da - PB&#x02009;~&#x02009;90%), p-cresylsulfate (PCS - 187&#x000a0;Da - PB&#x02009;~&#x02009;95%). To determine the total concentration, serum samples were first deproteinized by heat denaturation [<xref ref-type="bibr" rid="CR36">36</xref>] before HPLC analysis. IS and IAA (excitation &#x003bb;<sub>ex</sub>: 280&#x000a0;nm; emission &#x003bb;<sub>em</sub>: 340&#x000a0;nm) and PCS and PCG (&#x003bb;<sub>ex</sub>: 265&#x000a0;nm; &#x003bb;<sub>em</sub>: 290&#x000a0;nm) were determined by fluorescence analysis, and HA by UV detection at 245&#x000a0;nm [<xref ref-type="bibr" rid="CR37">37</xref>]. Free fractions were determined according to Fagugli et al. [<xref ref-type="bibr" rid="CR37">37</xref>] and serum total protein (TP) was analysed according to standard methods.</p></sec><sec id="Sec6"><title>Calculations</title><p>Reduction ratio (RR - %) of solutes was defined as a function of predialysis (C<sub>pre</sub>) and postdialysis concentrations (C<sub>post</sub>) of samples collected from the inlet blood line:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{R}\mathrm{R}\ \left(\%\right)=\frac{{\mathrm{C}}_{\mathrm{pre}}-{\mathrm{C}}_{\mathrm{post}}}{{\mathrm{C}}_{\mathrm{pre}}}\cdot 100 $$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mo>%</mml:mo></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">post</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#x022c5;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12882_2015_56_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p><p>During 8&#x000a0;h MPHD, RR was also calculated for the 0-240&#x000a0;min and the 240-480&#x000a0;min dialysis interval.</p><p>The dialyser extraction ratio (ER - %) was calculated as the relative change in concentration from the dialyser inlet (C<sub>inlet</sub>) towards the outlet (C<sub>outlet</sub>):<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{E}\mathrm{R}\ \left(\%\right)=\frac{{\mathrm{C}}_{\mathrm{inlet}}-{\mathrm{C}}_{\mathrm{outlet}}}{{\mathrm{C}}_{\mathrm{inlet}}}\cdot 100 $$\end{document}</tex-math><mml:math id="M4"><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mo>%</mml:mo></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">inlet</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">outlet</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">inlet</mml:mi></mml:msub></mml:mfrac><mml:mo>&#x022c5;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12882_2015_56_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p><p>Total solute removal (TSR - mg) at time point t was calculated from dialysate concentration in the chamber at that time point, and multiplied by either the volume of spent dialysate at time point t (SHD) or the dialysate volume in the chamber (MPHD). Total solute removal on weekly basis was calculated from TSR as measured and calculated in a single session and multiplied by the dialysis frequency per week.</p><p>Protein-bound solute concentrations at time point t were corrected for hemoconcentration by a factor (F) based on TP concentration predialysis versus time point t: F&#x02009;=&#x02009;TP<sub>pre</sub>/TP<sub>t</sub>. Likewise, dialyser outlet concentration (C<sub>outlet</sub>) was corrected by F&#x02009;=&#x02009;TP<sub>inlet</sub>/TP<sub>outlet</sub>.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>Data are expressed as mean&#x02009;&#x000b1;&#x02009;SD assuming normally distributed populations. Statistical analyses were carried out using the parametric <italic>t</italic>-test for paired samples. A P&#x02009;&#x02264;&#x02009;0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS Statistics 21 (SPSS Inc, Chicago, IL) for Windows (Microsoft Corp, Redmond,WA).</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><p>The nine included patients (female n&#x02009;=&#x02009;3) were 63.4&#x02009;&#x000b1;&#x02009;12.7&#x000a0;years old and spent 7.1&#x02009;&#x000b1;&#x02009;4.4&#x000a0;years on dialysis. Renal diagnoses were: hypertensive nephropathy (n&#x02009;=&#x02009;3), polycystic renal disease (n&#x02009;=&#x02009;1), glomerulonephritis (n&#x02009;=&#x02009;1), chronic interstitial nephropathy (n&#x02009;=&#x02009;1), and unknown (n&#x02009;=&#x02009;3). Five patients had a residual daily diuresis of more than 300&#x000a0;mL/day. Patients dry weight was 79.8&#x02009;&#x000b1;&#x02009;19.4&#x000a0;kg, resulting in a calculated TBW of 46.5&#x02009;&#x000b1;&#x02009;11.2&#x000a0;kg. Accordingly, MPHD dialysate volume was 22.9&#x02009;&#x000b1;&#x02009;5.0&#x000a0;L (range 13.8 to 30.4&#x000a0;L). Blood flow was 279&#x02009;&#x000b1;&#x02009;43&#x000a0;mL/min during SHD and 279&#x02009;&#x000b1;&#x02009;41&#x000a0;mL/min during MPHD (N.S.).</p><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the variation in serum concentration during SHD (squares - full line) and MPHD (diamonds - dotted line) for p-cresylglucuronide (PCG), hippuric acid (HA), indole acetic acid (IAA), indoxyl sulfate (IS), and p-cresylsulfate (PCS). Serum concentrations at start of the dialysis session were not different between both modalities in the individual patients (N.S.). The large standard deviations indicate important inter-patient variability in serum concentrations of these solutes. Nevertheless, it was in all patients consistently observed that concentration reductions were much smaller with 8&#x000a0;h MPHD as compared to 4&#x000a0;h SHD. In addition, it is noteworthy that during the second half of the 8&#x000a0;h MPHD, nearly no further change in concentration reduction was observed (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>Serum concentrations at different time points during standard hemodialysis SHD (squares - full line) and multipass hemodialysis MPHD (diamonds - dotted line) for p-cresylglucuronide (PCG -panel <bold> A</bold>), hippuric acid (HA - panel<bold> B</bold>), indole acetic acid (IAA - panel<bold> C</bold>), indoxyl sulfate (IS - panel <bold>D</bold>), and p-cresylsulfate (PCS - panel<bold> E</bold>). *P&#x02009;&#x0003c;&#x02009;0.05 MPHD <italic>versus</italic> SHD. &#x02020;P&#x02009;=&#x02009;0.053 MPHD <italic>versus</italic> SHD.</p></caption><graphic xlink:href="12882_2015_56_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Reduction ratios (%) for different protein-bound solutes in SHD and MPHD</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Solute</bold>
</th><th>
<bold>SHD</bold>
</th><th colspan="3">
<bold>MPHD</bold>
</th></tr><tr valign="top"><th/><th>
<bold>0-240&#x000a0;min</bold>
</th><th>
<bold>0-240&#x000a0;min</bold>
</th><th>
<bold>240-480&#x000a0;min</bold>
</th><th>
<bold>0-480&#x000a0;min</bold>
</th></tr></thead><tbody><tr valign="top"><td>Total PCG</td><td>81&#x02009;&#x000b1;&#x02009;7</td><td>51&#x02009;&#x000b1;&#x02009;5</td><td>9&#x02009;&#x000b1;&#x02009;9&#x02020;</td><td>55&#x02009;&#x000b1;&#x02009;6*&#x02020;</td></tr><tr valign="top"><td>Total HA</td><td>68&#x02009;&#x000b1;&#x02009;10</td><td>42&#x02009;&#x000b1;&#x02009;7</td><td>1&#x02009;&#x000b1;&#x02009;37&#x02020;</td><td>43&#x02009;&#x000b1;&#x02009;16*</td></tr><tr valign="top"><td>Total IAA</td><td>46&#x02009;&#x000b1;&#x02009;8</td><td>25&#x02009;&#x000b1;&#x02009;5</td><td>9&#x02009;&#x000b1;&#x02009;13&#x02020;</td><td>32&#x02009;&#x000b1;&#x02009;8*</td></tr><tr valign="top"><td>Total IS</td><td>41&#x02009;&#x000b1;&#x02009;11</td><td>14&#x02009;&#x000b1;&#x02009;6</td><td>10&#x02009;&#x000b1;&#x02009;12</td><td>23&#x02009;&#x000b1;&#x02009;11*&#x02020;</td></tr><tr valign="top"><td>Total PCS</td><td>37&#x02009;&#x000b1;&#x02009;9</td><td>10&#x02009;&#x000b1;&#x02009;9</td><td>6&#x02009;&#x000b1;&#x02009;18</td><td>16&#x02009;&#x000b1;&#x02009;15*</td></tr><tr valign="top"><td>Free PCG</td><td>84&#x02009;&#x000b1;&#x02009;5</td><td>51&#x02009;&#x000b1;&#x02009;5</td><td>10&#x02009;&#x000b1;&#x02009;10&#x02020;</td><td>56&#x02009;&#x000b1;&#x02009;6*&#x02020;</td></tr><tr valign="top"><td>Free HA</td><td>78&#x02009;&#x000b1;&#x02009;8</td><td>45&#x02009;&#x000b1;&#x02009;11</td><td>&#x02212;5&#x02009;&#x000b1;&#x02009;38&#x02020;</td><td>44&#x02009;&#x000b1;&#x02009;16*</td></tr><tr valign="top"><td>Free IAA</td><td>67&#x02009;&#x000b1;&#x02009;28</td><td>33&#x02009;&#x000b1;&#x02009;13</td><td>8&#x02009;&#x000b1;&#x02009;21&#x02020;</td><td>39&#x02009;&#x000b1;&#x02009;18*</td></tr><tr valign="top"><td>Free IS</td><td>59&#x02009;&#x000b1;&#x02009;17</td><td>&#x02212;7&#x02009;&#x000b1;&#x02009;33</td><td>7&#x02009;&#x000b1;&#x02009;43</td><td>&#x02212;2&#x02009;&#x000b1;&#x02009;55*</td></tr><tr valign="top"><td>Free PCS</td><td>74&#x02009;&#x000b1;&#x02009;11</td><td>&#x02212;1&#x02009;&#x000b1;&#x02009;44</td><td>7&#x02009;&#x000b1;&#x02009;39</td><td>7&#x02009;&#x000b1;&#x02009;51*</td></tr></tbody></table><table-wrap-foot><p>SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate; PCS: p-cresylsulfate.</p><p>*P&#x02009;&#x0003c;&#x02009;0.05 <italic>versus</italic> SHD; &#x02020;P&#x02009;&#x0003c;&#x02009;0.05 <italic>versus</italic> MPHD<sub>0-240min</sub>.</p></table-wrap-foot></table-wrap></p><p>Already at 60&#x000a0;min after dialysis start, a huge difference is observed between the extraction ratio for total and free fractions during SHD and MPHD, due to the recirculation in the latter modality (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Extraction in the hemodialyser for total concentrations of protein-bound solutes is a factor 1.4-1.8 (PCG, HA, IAA) and 3&#x02013;4 (IS, PCS) larger with SHD as compared to MPHD, while for the free fractions of these solutes, it is a factor 1.4-1.6 (PCG, HA, IAA) and 2.1-2.5 (IS, PCS). Hence, there is an inverse correlation between extraction ratio and percentage protein binding in both SHD (R&#x02009;=&#x02009;&#x02212;0.98) and MPHD (R&#x02009;=&#x02009;&#x02212;0.99), but extraction of highly bound solutes like IS and PCS is even more hampered in MPHD compared to SHD.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Extraction ratios (%) at 60&#x000a0;min during SHD and MPHD for total and free fractions of different protein-bound solutes</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Solute</bold>
</th><th>
<bold>SHD</bold>
</th><th>
<bold>MPHD</bold>
</th><th>
<bold>SHD/MPHD</bold>
</th></tr></thead><tbody><tr valign="top"><td>Total PCG</td><td>73&#x02009;&#x000b1;&#x02009;15</td><td>53&#x02009;&#x000b1;&#x02009;8*</td><td>1.4</td></tr><tr valign="top"><td>Total HA</td><td>54&#x02009;&#x000b1;&#x02009;10</td><td>31&#x02009;&#x000b1;&#x02009;19*</td><td>1.7</td></tr><tr valign="top"><td>Total IAA</td><td>29&#x02009;&#x000b1;&#x02009;8</td><td>16&#x02009;&#x000b1;&#x02009;8*</td><td>1.8</td></tr><tr valign="top"><td>Total IS</td><td>13&#x02009;&#x000b1;&#x02009;5</td><td>5&#x02009;&#x000b1;&#x02009;5*</td><td>2.9</td></tr><tr valign="top"><td>Total PCS</td><td>11&#x02009;&#x000b1;&#x02009;6</td><td>3&#x02009;&#x000b1;&#x02009;5*</td><td>3.9</td></tr><tr valign="top"><td>Free PCG</td><td>78&#x02009;&#x000b1;&#x02009;10</td><td>55&#x02009;&#x000b1;&#x02009;9*</td><td>1.4</td></tr><tr valign="top"><td>Free HA</td><td>65&#x02009;&#x000b1;&#x02009;11</td><td>43&#x02009;&#x000b1;&#x02009;8*</td><td>1.5</td></tr><tr valign="top"><td>Free IAA</td><td>49&#x02009;&#x000b1;&#x02009;23</td><td>31&#x02009;&#x000b1;&#x02009;12*</td><td>1.6</td></tr><tr valign="top"><td>Free IS</td><td>36&#x02009;&#x000b1;&#x02009;9</td><td>17&#x02009;&#x000b1;&#x02009;10*</td><td>2.1</td></tr><tr valign="top"><td>Free PCS</td><td>38&#x02009;&#x000b1;&#x02009;15</td><td>15&#x02009;&#x000b1;&#x02009;10*</td><td>2.5</td></tr></tbody></table><table-wrap-foot><p>SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate; PCS: p-cresylsulfate.</p><p>*P&#x02009;&#x0003c;&#x02009;0.05 versus SHD.</p></table-wrap-foot></table-wrap></p><p>Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> clearly indicates that the cumulative total solute removal (TSR) with MPHD <italic>versus</italic> SHD is, for all studied solutes, much smaller. Of note, TSR seems to saturate after 4&#x000a0;h MPHD. The normalized TSR for the amount of used dialysate was a factor 3&#x02013;3.9 (PCG, HA, IAA) and 1.8-1.9 (IS, PCS) larger with MPHD as compared to SHD (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), indicating the relative efficiency of the MPHD modality with regard to water use.<fig id="Fig2"><label>Figure 2</label><caption><p>Cumulative total solute removal (TSR) at different time points during standard hemodialysis SHD (squares - full line) and multipass hemodialysis MPHD (diamonds - dotted line) for p-cresylglucuronide (PCG - panel<bold> A</bold>), hippuric acid (HA - panel<bold> B</bold>), indole acetic acid (IAA - panel<bold> C</bold>), and indoxyl sulfate (IS - panel<bold> D</bold>), p-cresylsulfate (PCS - panel<bold> E</bold>). *P&#x02009;&#x0003c;&#x02009;0.05 MPHD <italic>versus</italic> SHD.</p></caption><graphic xlink:href="12882_2015_56_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Total solute removal per litre used dialysate (mg/L) and the ratio of total solute removal during MPHD</bold>
<bold><italic>versus</italic></bold>
<bold>SHD</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Solute</bold>
</th><th>
<bold>SHD</bold>
</th><th colspan="2">
<bold>MPHD</bold>
</th><th rowspan="2">
<inline-formula id="IEq1"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \frac{{\mathbf{MPHD}}_{\mathbf{0}\mathbf{\hbox{-}}\mathbf{240}}}{\mathbf{SHD}} $$\end{document}</tex-math><mml:math id="M6"><mml:mfrac><mml:msub><mml:mi mathvariant="bold">MPHD</mml:mi><mml:mrow><mml:mn mathvariant="bold">0</mml:mn><mml:mo mathvariant="bold">&#x02010;</mml:mo><mml:mn mathvariant="bold">240</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="bold">S</mml:mi><mml:mi mathvariant="bold">H</mml:mi><mml:mi mathvariant="bold">D</mml:mi></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="12882_2015_56_Article_IEq1.gif"/></alternatives></inline-formula>
</th><th rowspan="2">
<inline-formula id="IEq2"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \frac{{\mathbf{MPHD}}_{\mathbf{0}\mathbf{\hbox{-}}\mathbf{480}}}{\mathbf{SHD}} $$\end{document}</tex-math><mml:math id="M8"><mml:mfrac><mml:msub><mml:mi mathvariant="bold">MPHD</mml:mi><mml:mrow><mml:mn mathvariant="bold">0</mml:mn><mml:mo mathvariant="bold">&#x02010;</mml:mo><mml:mn mathvariant="bold">480</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="bold">S</mml:mi><mml:mi mathvariant="bold">H</mml:mi><mml:mi mathvariant="bold">D</mml:mi></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="12882_2015_56_Article_IEq2.gif"/></alternatives></inline-formula>
</th></tr><tr valign="top"><th/><th>
<bold>0-240&#x000a0;min</bold>
</th><th>
<bold>0-240&#x000a0;min</bold>
</th><th>
<bold>0-480&#x000a0;min</bold>
</th></tr></thead><tbody><tr valign="top"><td>Total PCG</td><td>1.29&#x02009;&#x000b1;&#x02009;1.22</td><td>4.22&#x02009;&#x000b1;&#x02009;3.57</td><td>4.71&#x02009;&#x000b1;&#x02009;3.93*&#x02020;</td><td>3.6&#x02009;&#x000b1;&#x02009;1.4</td><td>3.9&#x02009;&#x000b1;&#x02009;1.7</td></tr><tr valign="top"><td>Total HA</td><td>5.35&#x02009;&#x000b1;&#x02009;5.39</td><td>10.4&#x02009;&#x000b1;&#x02009;9.2</td><td>12.5&#x02009;&#x000b1;&#x02009;11.3*&#x02020;</td><td>2.7&#x02009;&#x000b1;&#x02009;1.3</td><td>3.0&#x02009;&#x000b1;&#x02009;1.0</td></tr><tr valign="top"><td>Total IAA</td><td>0.22&#x02009;&#x000b1;&#x02009;0.27</td><td>0.52&#x02009;&#x000b1;&#x02009;0.44</td><td>0.57&#x02009;&#x000b1;&#x02009;0.50</td><td>3.4&#x02009;&#x000b1;&#x02009;1.5</td><td>3.7&#x02009;&#x000b1;&#x02009;1.9</td></tr><tr valign="top"><td>Total IS</td><td>1.29&#x02009;&#x000b1;&#x02009;0.79</td><td>2.43&#x02009;&#x000b1;&#x02009;1.72</td><td>2.54&#x02009;&#x000b1;&#x02009;1.76*</td><td>1.8&#x02009;&#x000b1;&#x02009;0.6</td><td>1.8&#x02009;&#x000b1;&#x02009;0.7</td></tr><tr valign="top"><td>Total PCS</td><td>0.83&#x02009;&#x000b1;&#x02009;0.50</td><td>1.60&#x02009;&#x000b1;&#x02009;0.87</td><td>1.56&#x02009;&#x000b1;&#x02009;0.92*</td><td>2.0&#x02009;&#x000b1;&#x02009;0.9</td><td>1.9&#x02009;&#x000b1;&#x02009;0.9</td></tr></tbody></table><table-wrap-foot><p>SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate; PCS: p-cresylsulfate.</p><p>*P&#x02009;&#x0003c;&#x02009;0.05 <italic>versus</italic> SHD; &#x02020;P&#x02009;&#x0003c;&#x02009;0.05 <italic>versus</italic> MPHD<sub>0-240min</sub>.</p></table-wrap-foot></table-wrap></p><p>When results of the experimental single session were extrapolated to a weekly basis, the absolute TSR during 6 times 8&#x000a0;h MPHD <italic>versus</italic> 3 times 4&#x000a0;h SHD was larger for PCG and IAA (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), not different for HA and smaller for IS and PCS. For 6 times 4&#x000a0;h MPHD <italic>versus</italic> 3 times 4&#x000a0;h SHD, TSR is only larger for PCG while smaller for IS and PCS, and for 6 times 2&#x000a0;h MPHD <italic>versus</italic> 3 times SHD, TSR is significantly smaller for HA, IS, and PCS.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Weekly total solute removal (mg) for 3 times 4&#x000a0;h SHD, 6 times 2&#x000a0;h MPHD, 6 times 4&#x000a0;h MPHD, and 6 times 8&#x000a0;h MPHD for different protein-bound solutes</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Solute</bold>
</th><th>
<bold>3x4 h SHD</bold>
</th><th>
<bold>6x2 h MPHD</bold>
</th><th>
<bold>6x4 h MPHD</bold>
</th><th>
<bold>6x8 h MPHD</bold>
</th></tr></thead><tbody><tr valign="top"><td>Total PCG</td><td>480&#x02009;&#x000b1;&#x02009;458</td><td>498&#x02009;&#x000b1;&#x02009;452</td><td>655&#x02009;&#x000b1;&#x02009;592*</td><td>729&#x02009;&#x000b1;&#x02009;650*&#x02020;</td></tr><tr valign="top"><td>Total HA</td><td>1985&#x02009;&#x000b1;&#x02009;2010</td><td>1338&#x02009;&#x000b1;&#x02009;1296*</td><td>1738&#x02009;&#x000b1;&#x02009;1688</td><td>2104&#x02009;&#x000b1;&#x02009;2096&#x02020;</td></tr><tr valign="top"><td>Total IAA</td><td>83&#x02009;&#x000b1;&#x02009;101</td><td>69&#x02009;&#x000b1;&#x02009;70</td><td>89&#x02009;&#x000b1;&#x02009;90</td><td>98&#x02009;&#x000b1;&#x02009;105*</td></tr><tr valign="top"><td>Total IS</td><td>478&#x02009;&#x000b1;&#x02009;291</td><td>308&#x02009;&#x000b1;&#x02009;232*</td><td>388&#x02009;&#x000b1;&#x02009;314*</td><td>406&#x02009;&#x000b1;&#x02009;320*</td></tr><tr valign="top"><td>Total PCS</td><td>306&#x02009;&#x000b1;&#x02009;183</td><td>199&#x02009;&#x000b1;&#x02009;112*</td><td>246&#x02009;&#x000b1;&#x02009;148*</td><td>241&#x02009;&#x000b1;&#x02009;155**</td></tr></tbody></table><table-wrap-foot><p>SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate; PCS: p-cresylsulfate.</p><p>*P&#x02009;&#x0003c;&#x02009;0.05 <italic>versus</italic> 3x4 h SHD; **P&#x02009;=&#x02009;0.57 <italic>versus</italic> 3x4 h SHD; &#x02020;P&#x02009;&#x0003c;&#x02009;0.05 <italic>versus</italic> 6x4 h MPHD.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>In this cross-over study comparing 4&#x000a0;h standard hemodialysis (SHD) with 8&#x000a0;h multipass hemodialysis (MPHD), concentration reduction and total solute removal were assessed for the protein-bound solutes p-cresylglucuronide (PCG), hippuric acid (HA), indole acetic acid (IAA), indoxyl sulfate (IS), and p-cresylsulfate (PCS). We found that already at 60&#x000a0;min after dialysis start, the extraction ratio in the hemodialyser was a factor 1.4-4 lower with MPHD <italic>versus</italic> SHD, resulting in lower reduction ratios and total solute removal. When TSR was calculated per litre of dialysate spent, MPHD appeared to be superior.</p><p>It was recently demonstrated that MPHD resulted in superior removal of small and middle molecular weight solutes when applied as 6 times/week 8&#x000a0;h dialysis, an effect that was already demonstrated previously using another batch system (Genius&#x000ae;, Fresenius Medical Care) [<xref ref-type="bibr" rid="CR4">4</xref>]. Our current results add to this knowledge that MPHD applied in this regimen results in equal total solute removal for light and moderately protein-bound solutes, but lower removal for highly protein-bound solutes as compared to standard 3 times weekly hemodialysis. Most likely, this can be explained by the fact that only the free solute can pass across the membrane. As the serum concentration of free solute is rather low, and as the dialysate is recycled, there is a rapid equilibration between the concentrations of the free solute in the serum and in the dialysate. As a result, replenishment of the pool of free toxin in the serum, either by loosening from the protein or by rebound from other compartments, has no effect on solute removal, as the diffusive gradient with the dialysate is lacking. Indeed, we observe (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) that after some hours of dialysis, there is a plateau of the concentration in the dialysate, and accordingly, a significantly lower extraction ratio in the hemodialyser is observed already after 60&#x000a0;min. After this, no further solute removal is observed. The timing of this plateau phase comes more early as the solute is more strongly protein-bound. Extending the dialysis session is accordingly of no use to increase solute removal of protein-bound toxins when small volumes of dialysate are recycled.</p><p>For middle molecular structures such as &#x003b2;<sub>2</sub>-microglobulin, this diffusive transport over the dialysis membrane is much slower, so the equilibration/saturation is also occurring at a slower rate. An increase of dialysis time from 4 to 8&#x000a0;hours, maintaining the same amount of processed blood and dialysate, previously demonstrated a 81% higher &#x003b2;<sub>2</sub>-microglobulin removal, a phenomenon that was much less pronounced (26-36% increase) for the small water soluble solutes urea and creatinine [<xref ref-type="bibr" rid="CR4">4</xref>]. This effect can be attributed to the slow transport of &#x003b2;<sub>2</sub>-microglobulin between the extraplasmatic and plasmatic compartment [<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>], resulting in a substantial rebound after conventional and short hemodialysis [<xref ref-type="bibr" rid="CR40">40</xref>]. During extended dialysis, the solute is allowed more time to shift between compartments. Accordingly, extending the dialysis session allows the serum pool of the middle molecule to be replenished from other compartments, resulting in an increase in solute removal even when recycling the dialysate, as demonstrated previously [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>A limitation of our study might be the mathematical extrapolation of the removal during a single session to the removal on weekly basis. Theoretically, since predialysis concentrations of toxins can be decreased in frequent dialysis, solute removal could be overestimated with frequent MPHD. However, as we are dealing with protein-bound solutes, only the free fraction can be eliminated during the dialysis session such that total removal is very low. Hence, it is likely that this free fraction is completely restored during the interdialytic interval, which was also found by Fagugli et al. investigating removal of protein-bound solutes in short daily dialysis (6 times weekly 2&#x000a0;hours) as compared to standard hemodialysis (3 times weekly 4&#x000a0;hours), even with a regular dialysis monitor and dialysate flow, so that saturation of dialysate could not play a role [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>It could be hypothesized that in order to increase solute removal of protein-bound toxins, one needs to extend total weekly treatment time, and use sufficiently high ratio of dialysate to blood flow. A recent kinetic analysis supported this hypothesis [<xref ref-type="bibr" rid="CR41">41</xref>]. If it is intended to use recycling of dialysate, an absorbent should be added to the dialysate system to keep the concentration of the free fraction of protein-bound solutes as low as possible.</p><p>Although it appears that MPHD is less suitable than SHD to remove protein-bound solutes, the advantage of MPHD is mainly the relatively higher amount of solute removed per litre of dialysate (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). This makes the multipass system a suitable alternative to apply in the setting of daily extended dialysis at home [<xref ref-type="bibr" rid="CR42">42</xref>], where the classical setup implies substantial technical modifications and results in a high consumption of water and electricity. The economy in water consumption is 33% (240&#x000a0;L/week <italic>versus</italic> 360&#x000a0;L/week), as more frequent dialysis is needed. Whereas this seems an impressive saving, we need to realize that water consumption is with 4-11% only a limited part of the carbon foot print of dialysis treatment, as compared to 35.7% for pharmaceuticals and 23.4% for medical equipment.</p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusion</title><p>MPHD appears to have some interesting features for use in the home setting, and results in more efficient use of dialysate. However, the currently proposed regimen of 6 times/week 8&#x000a0;hours seems to have no advantage over 3 times/week SHD in terms of removal of protein-bound solutes.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>C</term><def><p>Concentration</p></def></def-item><def-item><term>ER</term><def><p>Extraction ratio</p></def></def-item><def-item><term>HA</term><def><p>Hippuric acid</p></def></def-item><def-item><term>HD</term><def><p>Hemodialysis</p></def></def-item><def-item><term>HPLC</term><def><p>High performance liquid chromatography</p></def></def-item><def-item><term>IAA</term><def><p>Indole acetic acid</p></def></def-item><def-item><term>IS</term><def><p>Indoxyl sulfate</p></def></def-item><def-item><term>MPHD</term><def><p>Multipass hemodialysis</p></def></def-item><def-item><term>N.S.</term><def><p>Non significant</p></def></def-item><def-item><term>PB</term><def><p>Protein binding</p></def></def-item><def-item><term>PBS</term><def><p>Protein-bound solutes</p></def></def-item><def-item><term>PCG</term><def><p>p-cresylglucuronide</p></def></def-item><def-item><term>PCS</term><def><p>p-cresylsulfate</p></def></def-item><def-item><term>RR</term><def><p>Reduction ratio</p></def></def-item><def-item><term>SHD</term><def><p>Standard hemodialysis (PBS)</p></def></def-item><def-item><term>TBW</term><def><p>Total body water</p></def></def-item><def-item><term>TP</term><def><p>Total protein</p></def></def-item><def-item><term>TSR</term><def><p>Total solute removal</p></def></def-item><def-item><term>UF</term><def><p>Ultrafiltration</p></def></def-item></def-list></glossary><fn-group><fn><p>Robert Smith Pedersen deceased.</p></fn><fn><p><bold>Competing interests</bold></p><p>RSP formerly owned shares in Flexdialysis ApS. However, R.S.P. died before the manuscript could be completed. The other authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>SE analysed and interpreted the data, performed the statistical analysis, and drafted the manuscript. WVB interpreted the data and co-drafted the manuscript. MA participated in the design and the execution of the study. GG coordinated the analytical determinations and interpreted the data. RSP participated in the design and the execution of the study. JH participated in the design of the study and has given final approval of the version to be published. All authors (except RSP who died previously) read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>Unfortunately, RSP, who was a major contributor to the conduct of this investigation, died before the manuscript could be completed.</p></fn></fn-group><ack><title>Acknowledgements</title><p>R.S.P. earned consulting honoraria from Flexdialysis A/S. The authors are indebted to the laboratory staff M. Van Landschoot, M.A. Waterloos, and S. Lobbestael for their technical assistance.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayus</surname><given-names>JC</given-names></name><name><surname>Mizani</surname><given-names>MR</given-names></name><name><surname>Achinger</surname><given-names>SG</given-names></name><name><surname>Thadhani</surname><given-names>R</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><fpage>2778</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1681/ASN.2005040392</pub-id><pub-id pub-id-type="pmid">16033855</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Levin</surname><given-names>NW</given-names></name><name><surname>Beck</surname><given-names>GJ</given-names></name><name><surname>Depner</surname><given-names>TA</given-names></name><name><surname>Eggers</surname><given-names>PW</given-names></name><name><surname>Gassman</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>In-center hemodialysis six times per week versus three times per week</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>2287</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001593</pub-id><pub-id pub-id-type="pmid">21091062</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culleton</surname><given-names>BF</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Klarenbach</surname><given-names>SW</given-names></name><name><surname>Mortis</surname><given-names>G</given-names></name><name><surname>Scott-Douglas</surname><given-names>N</given-names></name><name><surname>Quinn</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial</article-title><source>JAMA</source><year>2007</year><volume>298</volume><fpage>1291</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.298.11.1291</pub-id><pub-id pub-id-type="pmid">17878421</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eloot</surname><given-names>S</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name><name><surname>Dhondt</surname><given-names>A</given-names></name><name><surname>Van de Wynkele</surname><given-names>H</given-names></name><name><surname>Glorieux</surname><given-names>G</given-names></name><name><surname>Verdonck</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of hemodialysis duration on the removal of uremic retention solutes</article-title><source>Kidney Int</source><year>2008</year><volume>73</volume><fpage>765</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002750</pub-id><pub-id pub-id-type="pmid">18160958</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eloot</surname><given-names>S</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name><name><surname>Dhondt</surname><given-names>A</given-names></name><name><surname>De Smet</surname><given-names>R</given-names></name><name><surname>Marescau</surname><given-names>B</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>2225</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp059</pub-id><pub-id pub-id-type="pmid">19225018</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>YN</given-names></name><name><surname>Larive</surname><given-names>B</given-names></name><name><surname>Painter</surname><given-names>P</given-names></name><name><surname>Kaysen</surname><given-names>GA</given-names></name><name><surname>Lindsay</surname><given-names>RM</given-names></name><name><surname>Nissenson</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials</article-title><source>Clin J Am Soc Nephrol</source><year>2012</year><volume>7</volume><fpage>782</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.2215/CJN.10601011</pub-id><pub-id pub-id-type="pmid">22422538</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>PJ</given-names></name><name><surname>Pierratos</surname><given-names>A</given-names></name></person-group><article-title>Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>102</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1056/NEJM200101113440204</pub-id><pub-id pub-id-type="pmid">11150360</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaber</surname><given-names>BL</given-names></name><name><surname>Schiller</surname><given-names>B</given-names></name><name><surname>Burkart</surname><given-names>JM</given-names></name><name><surname>Daoui</surname><given-names>R</given-names></name><name><surname>Kraus</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><fpage>1049</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.2215/CJN.10451110</pub-id><pub-id pub-id-type="pmid">21415315</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maduell</surname><given-names>F</given-names></name><name><surname>Navarro</surname><given-names>V</given-names></name><name><surname>Torregrosa</surname><given-names>E</given-names></name><name><surname>Rius</surname><given-names>A</given-names></name><name><surname>Dicenta</surname><given-names>F</given-names></name><name><surname>Cruz</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration</article-title><source>Kidney Int</source><year>2003</year><volume>64</volume><fpage>305</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00043.x</pub-id><pub-id pub-id-type="pmid">12787423</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarlane</surname><given-names>PA</given-names></name><name><surname>Bayoumi</surname><given-names>AM</given-names></name><name><surname>Pierratos</surname><given-names>A</given-names></name><name><surname>Redelmeier</surname><given-names>DA</given-names></name></person-group><article-title>The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis</article-title><source>Kidney Int</source><year>2003</year><volume>64</volume><fpage>1004</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00157.x</pub-id><pub-id pub-id-type="pmid">12911550</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ok</surname><given-names>E</given-names></name><name><surname>Duman</surname><given-names>S</given-names></name><name><surname>Asci</surname><given-names>G</given-names></name><name><surname>Tumuklu</surname><given-names>M</given-names></name><name><surname>Onen</surname><given-names>SO</given-names></name><name><surname>Kayikcioglu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study</article-title><source>Nephrol Dial Transplant</source><year>2011</year><volume>26</volume><fpage>1287</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq724</pub-id><pub-id pub-id-type="pmid">21148270</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocco</surname><given-names>MV</given-names></name><name><surname>Lockridge</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Beck</surname><given-names>GJ</given-names></name><name><surname>Eggers</surname><given-names>PW</given-names></name><name><surname>Gassman</surname><given-names>JJ</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><etal/></person-group><article-title>The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial</article-title><source>Kidney Int</source><year>2011</year><volume>80</volume><fpage>1080</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.213</pub-id><pub-id pub-id-type="pmid">21775973</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>GO</given-names></name><name><surname>Kjellstrand</surname><given-names>C</given-names></name><name><surname>Freitas</surname><given-names>T</given-names></name><name><surname>Carrie</surname><given-names>BJ</given-names></name><name><surname>Zarghamee</surname><given-names>S</given-names></name></person-group><article-title>Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>42</volume><fpage>1020</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ajkd.2003.07.020</pub-id><pub-id pub-id-type="pmid">14582046</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>M</given-names></name><name><surname>Manns</surname><given-names>BJ</given-names></name><name><surname>Klarenbach</surname><given-names>S</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Hemmelgarn</surname><given-names>B</given-names></name><name><surname>Culleton</surname><given-names>B</given-names></name></person-group><article-title>The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial</article-title><source>Hemodial Int</source><year>2010</year><volume>14</volume><fpage>174</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1542-4758.2009.00418.x</pub-id><pub-id pub-id-type="pmid">20041960</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>Eloot</surname><given-names>S</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name><name><surname>Lameire</surname><given-names>N</given-names></name></person-group><article-title>Less water for haemodialysis: is multiple pass the future pace to go?</article-title><source>Nephrol Dial Transplant</source><year>2013</year><volume>28</volume><fpage>1067</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfs546</pub-id><pub-id pub-id-type="pmid">23291373</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eloot</surname><given-names>S</given-names></name><name><surname>Dhondt</surname><given-names>A</given-names></name><name><surname>Vierendeels</surname><given-names>J</given-names></name><name><surname>De Wachter</surname><given-names>D</given-names></name><name><surname>Verdonck</surname><given-names>P</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>Temperature and concentration distribution within the Genius dialysate container</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><fpage>2962</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfm356</pub-id><pub-id pub-id-type="pmid">17567650</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassbinder</surname><given-names>W</given-names></name></person-group><article-title>Experience with the GENIUS hemodialysis system</article-title><source>Kidney Blood Press Res</source><year>2003</year><volume>26</volume><fpage>96</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000070990</pub-id><pub-id pub-id-type="pmid">12771533</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhondt</surname><given-names>AW</given-names></name><name><surname>Vanholder</surname><given-names>RC</given-names></name><name><surname>De Smet</surname><given-names>RV</given-names></name><name><surname>Claus</surname><given-names>SA</given-names></name><name><surname>Waterloos</surname><given-names>MA</given-names></name><name><surname>Glorieux</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy</article-title><source>Kidney Int</source><year>2003</year><volume>63</volume><fpage>1540</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00862.x</pub-id><pub-id pub-id-type="pmid">12631371</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>WR</given-names></name><name><surname>Turk</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>The NxStage system one</article-title><source>Semin Dial</source><year>2004</year><volume>17</volume><fpage>167</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/j.0894-0959.2004.17220.x</pub-id><pub-id pub-id-type="pmid">15043625</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaf</surname><given-names>JG</given-names></name><name><surname>Axelsen</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>RS</given-names></name></person-group><article-title>Multipass haemodialysis: a novel dialysis modality</article-title><source>Nephrol Dial Transplant</source><year>2013</year><volume>28</volume><fpage>1255</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfs484</pub-id><pub-id pub-id-type="pmid">23136214</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Mancini</surname><given-names>E</given-names></name><name><surname>Bolzani</surname><given-names>R</given-names></name><name><surname>Boggi</surname><given-names>R</given-names></name><name><surname>Cagnoli</surname><given-names>L</given-names></name><name><surname>Francioso</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>52</volume><fpage>507</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.05.011</pub-id><pub-id pub-id-type="pmid">18617304</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>De Smet</surname><given-names>R</given-names></name></person-group><article-title>Pathophysiologic effects of uremic retention solutes</article-title><source>J Am Soc Nephrol</source><year>1999</year><volume>10</volume><fpage>1815</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10446951</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>Baurmeister</surname><given-names>U</given-names></name><name><surname>Brunet</surname><given-names>P</given-names></name><name><surname>Cohen</surname><given-names>G</given-names></name><name><surname>Glorieux</surname><given-names>G</given-names></name><name><surname>Jankowski</surname><given-names>J</given-names></name></person-group><article-title>A bench to bedside view of uremic toxins</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>863</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007121377</pub-id><pub-id pub-id-type="pmid">18287557</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adijiang</surname><given-names>A</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Uramoto</surname><given-names>S</given-names></name><name><surname>Nishijima</surname><given-names>F</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name></person-group><article-title>Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>23</volume><fpage>1892</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfm861</pub-id><pub-id pub-id-type="pmid">18334529</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bammens</surname><given-names>B</given-names></name><name><surname>Evenepoel</surname><given-names>P</given-names></name><name><surname>Keuleers</surname><given-names>H</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><name><surname>Vanrenterghem</surname><given-names>Y</given-names></name></person-group><article-title>Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><fpage>1081</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000115</pub-id><pub-id pub-id-type="pmid">16421516</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreto</surname><given-names>FC</given-names></name><name><surname>Barreto</surname><given-names>DV</given-names></name><name><surname>Liabeuf</surname><given-names>S</given-names></name><name><surname>Meert</surname><given-names>N</given-names></name><name><surname>Glorieux</surname><given-names>G</given-names></name><name><surname>Temmar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><fpage>1551</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2215/CJN.03980609</pub-id><pub-id pub-id-type="pmid">19696217</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dou</surname><given-names>L</given-names></name><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Cerini</surname><given-names>C</given-names></name><name><surname>Faure</surname><given-names>V</given-names></name><name><surname>Sampol</surname><given-names>J</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name><etal/></person-group><article-title>The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>442</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00399.x</pub-id><pub-id pub-id-type="pmid">14717914</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liabeuf</surname><given-names>S</given-names></name><name><surname>Barreto</surname><given-names>DV</given-names></name><name><surname>Barreto</surname><given-names>FC</given-names></name><name><surname>Meert</surname><given-names>N</given-names></name><name><surname>Glorieux</surname><given-names>G</given-names></name><name><surname>Schepers</surname><given-names>E</given-names></name><etal/></person-group><article-title>Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>1183</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp592</pub-id><pub-id pub-id-type="pmid">19914995</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname><given-names>BK</given-names></name><name><surname>Bammens</surname><given-names>B</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><name><surname>Vanrenterghem</surname><given-names>Y</given-names></name><name><surname>Evenepoel</surname><given-names>P</given-names></name></person-group><article-title>Free p-cresol is associated with cardiovascular disease in hemodialysis patients</article-title><source>Kidney Int</source><year>2008</year><volume>73</volume><fpage>1174</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.31</pub-id><pub-id pub-id-type="pmid">18305466</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname><given-names>BK</given-names></name><name><surname>Van Kerckhoven</surname><given-names>S</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name><name><surname>Dehaen</surname><given-names>W</given-names></name><name><surname>Vanrenterghem</surname><given-names>Y</given-names></name><name><surname>Hoylaerts</surname><given-names>MF</given-names></name><etal/></person-group><article-title>The uremic retention solute p-cresyl sulfate and markers of endothelial damage</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>54</volume><fpage>891</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2009.04.022</pub-id><pub-id pub-id-type="pmid">19615803</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Tatematsu</surname><given-names>A</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name></person-group><article-title>Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography</article-title><source>Clin Chem</source><year>1988</year><volume>34</volume><fpage>2264</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3141084</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepers</surname><given-names>E</given-names></name><name><surname>Meert</surname><given-names>N</given-names></name><name><surname>Glorieux</surname><given-names>G</given-names></name><name><surname>Goeman</surname><given-names>J</given-names></name><name><surname>der EJ</surname><given-names>V</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><fpage>592</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfl584</pub-id><pub-id pub-id-type="pmid">17040995</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Tsuruoka</surname><given-names>S</given-names></name><name><surname>Ioka</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>C</given-names></name><name><surname>Akimoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><fpage>1780</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000340</pub-id><pub-id pub-id-type="pmid">16612331</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>MA</given-names></name><name><surname>Sanchez-Lozada</surname><given-names>LG</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name></person-group><article-title>Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction</article-title><source>J Hypertens</source><year>2010</year><volume>28</volume><fpage>1234</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20486275</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoccali</surname><given-names>C</given-names></name><name><surname>Maio</surname><given-names>R</given-names></name><name><surname>Mallamaci</surname><given-names>F</given-names></name><name><surname>Sesti</surname><given-names>G</given-names></name><name><surname>Perticone</surname><given-names>F</given-names></name></person-group><article-title>Uric acid and endothelial dysfunction in essential hypertension</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>1466</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1681/ASN.2005090949</pub-id><pub-id pub-id-type="pmid">16611716</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>Hoefliger</surname><given-names>N</given-names></name><name><surname>De</surname><given-names>SR</given-names></name><name><surname>Ringoir</surname><given-names>S</given-names></name></person-group><article-title>Extraction of protein bound ligands from azotemic sera: comparison of 12 deproteinization methods</article-title><source>Kidney Int</source><year>1992</year><volume>41</volume><fpage>1707</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/ki.1992.244</pub-id><pub-id pub-id-type="pmid">1501426</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagugli</surname><given-names>RM</given-names></name><name><surname>De Smet</surname><given-names>R</given-names></name><name><surname>Buoncristiani</surname><given-names>U</given-names></name><name><surname>Lameire</surname><given-names>N</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis</article-title><source>Am J Kidney Dis</source><year>2002</year><volume>40</volume><fpage>339</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2002.34518</pub-id><pub-id pub-id-type="pmid">12148107</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odell</surname><given-names>RA</given-names></name><name><surname>Slowiaczek</surname><given-names>P</given-names></name><name><surname>Moran</surname><given-names>JE</given-names></name><name><surname>Schindhelm</surname><given-names>K</given-names></name></person-group><article-title>Beta 2-microglobulin kinetics in end-stage renal failure</article-title><source>Kidney Int</source><year>1991</year><volume>39</volume><fpage>909</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/ki.1991.114</pub-id><pub-id pub-id-type="pmid">2067207</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>XQ</given-names></name><name><surname>Gruner</surname><given-names>N</given-names></name><name><surname>Vienken</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>H</given-names></name></person-group><article-title>Validation of a two-pool model for the kinetics of beta2-microglobulin</article-title><source>Int J Artif Organs</source><year>2002</year><volume>25</volume><fpage>411</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12074339</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leypoldt</surname><given-names>JK</given-names></name><name><surname>Cheung</surname><given-names>AK</given-names></name><name><surname>Deeter</surname><given-names>RB</given-names></name></person-group><article-title>Rebound kinetics of beta2-microglobulin after hemodialysis</article-title><source>Kidney Int</source><year>1999</year><volume>56</volume><fpage>1571</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.1999.00669.x</pub-id><pub-id pub-id-type="pmid">10504510</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eloot</surname><given-names>S</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>Kinetics of protein-bound solutes during hemodialysis</article-title><source>Int J Artif Organs</source><year>2012</year><volume>35</volume><issue>8</issue><fpage>583</fpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanholder</surname><given-names>R</given-names></name><name><surname>Eloot</surname><given-names>S</given-names></name><name><surname>Neirynck</surname><given-names>N</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name></person-group><article-title>Home haemodialysis and uraemic toxin removal: does a happy marriage exist?</article-title><source>Nat Rev Nephrol</source><year>2012</year><volume>8</volume><fpage>579</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2012.189</pub-id><pub-id pub-id-type="pmid">22926247</pub-id></element-citation></ref></ref-list></back></article>